IL-33 – Medxy AI

Unveiling the Roles of Mast Cells and Endothelial Cells in IL-33/ST2 Pathway Dysregulation in COPD Lungs

By MedXY 07/20/2026

This study elucidates distinct cellular expression patterns of IL-33 and its receptor variants ST2L and sST2 in COPD lungs, highlighting mast cells and endothelial cells as key mediators in the distal lung immune response.

news Respiratory Specialties

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

By MedXY 09/19/2025

The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients with frequent exacerbations, supporting ongoing phase 3 studies.

Medical News news

Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention

By MedXY 08/30/2025

Recent research uncovers that long-term statin use may prevent certain inflammation-driven cancers by blocking IL-33, heralding new possibilities in cancer prevention strategies.